Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

L.A. McKeown

March 06, 2023

Presentation ACC 2023

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presenter: John P. Boehmer

March 05, 2023

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

Advertisement

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content